Background and objective: Adolescent idiopathic scoliosis (A.I.S.) is a disorder with a significant impact on health and self-image. This spinal deformity can affect between 2% and 4% of the adolescent population and may alter one’s quality of life. This study aims to assess the patient outcome, satisfaction, and quality of life following surgical treatment using the SRS-30 questionnaire. Materials and Methods: A number of 49 children and adolescent patients diagnosed with idiopathic scoliosis that had surgery were included in this study. They thoroughly completed the SRS-30 questionnaire before and after the surgery, based on which data analysis was carried on. Correlations between the test results and imagistic data (pre- and postoperative Cobb angle, correction rate of Cobb angle, number of instrumented spinal segments, and number of pedicle screws/laminar hooks used in the surgery) were performed. Results: Our results showed that 87.76% of the patients were girls, and the mean age at surgery was 14.83 years. Postoperatively, the Cobb angle improved significantly (p < 0.0001). The questionnaire domain “Satisfaction with management” improved dramatically after surgery, averaging 13.65 points (91% out of the maximum score). The average postoperative test score was 125.1 points. Statistically significant correlations were found between the correction rate and SRS-30 score improvement (p < 0.001), in total as well as per each domain of the survey, respectively. Comparing the questionnaire domains, “Self-image” was positively correlated with “Satisfaction with management” (p < 0.0001). Conclusions: Better correction rate led to higher values of SRS-30 score. Additionally, the younger the age at surgery is, the higher the score. The number of instrumented spinal segments does not alter the quality of life. Overall, the most crucial factor influencing patient satisfaction after surgical treatment is self-image.

Background. Research into the potential therapeutic applications of psilocybin has been ongoing for decades, with recent studies showing promising results in treating mental health conditions such as depression, anxiety, and addiction. Methods. The clinical trials that have been conducted so far regarding the therapeutic effects of psilocybin on psychiatric disorders were systematically reviewed in this article. PubMed, MEDLINE and Google Scholar databases were searched from January 1980 to March 2023. 17 articles met the eligibility criteria after identification and screening for title and abstract. Results. Articles were divided into groups according to the psychiatric disorder addressed. 13 articles studied the efficiency of psilocybin in the treatment of depressive symptoms. 10 articles were randomized or open-label trials with a range of 12 to 59 patients and 3 were follow-ups. 5 out of the 13 articles explored psilocybin efficiency in patients with anxiety and depression disorders in correlation to life-threatening diseases (different stages of cancer or HIV). Only one open-label trial addressed psilocybin effect in patients with obsessive compulsive disorder. 3 studies assessed psilocybin efficiency regarding addictions treatment: alcohol addiction (one open-label trial) and tobacco addiction (one open-label trial and one follow-up). Conclusions. Psilocybin shows promise as a potential therapeutic agent for various mental health conditions. Further research on larger groups of patients is needed to fully understand the therapeutic potential of psilocybin and to optimize dosing protocols and minimize potential adverse effects.